These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32860346)

  • 1. Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients.
    Abe T; Jujo K; Kametani M; Minami Y; Fukushima N; Saito K; Hagiwara N
    ESC Heart Fail; 2020 Oct; 7(5):2711-2724. PubMed ID: 32860346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction.
    Kocabaş U; Ergin I; Kıvrak T; Yılmaz Öztekin GM; Tanık VO; Özdemir İ; Avcı Demir F; Doğduş M; Şen T; Altınsoy M; Üstündağ S; Urgun ÖD; Sinan ÜY; Uygur B; Yeni M; Özçalık E
    ESC Heart Fail; 2023 Dec; 10(6):3677-3689. PubMed ID: 37804042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing Guideline-Directed Medical Therapy During Hospitalization Improves Prognosis in Patients With Worsening Heart Failure Requiring Readmissions.
    Matsukawa R; Kabu K; Koga E; Hara A; Kisanuki H; Sada M; Okabe K; Okahara A; Tokutome M; Kawai S; Ogawa K; Matsuura H; Mukai Y
    Circ J; 2024 Aug; 88(9):1416-1424. PubMed ID: 39034132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure.
    Henrysson J; Thunström E; Chen X; Fu M; Basic C
    ESC Heart Fail; 2023 Feb; 10(1):66-79. PubMed ID: 36161782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of adherence to guideline-directed therapy on risk of death in HF patients across an ejection fraction spectrum.
    Chen X; Kang Y; Dahlström U; Fu M
    ESC Heart Fail; 2023 Dec; 10(6):3656-3666. PubMed ID: 37803813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
    Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS
    Eur J Heart Fail; 2021 Sep; 23(9):1499-1511. PubMed ID: 34132001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction.
    Schupp T; Bertsch T; Reinhardt M; Abel N; Schmitt A; Lau F; Abumayyaleh M; Akin M; Weiß C; Weidner K; Behnes M; Akin I
    Eur J Prev Cardiol; 2024 Aug; 31(11):1347-1360. PubMed ID: 38513366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry.
    Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M
    Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
    Premchand RK; Sharma K; Mittal S; Monteiro R; Libbus I; Ardell JL; Gregory DD; KenKnight BH; Amurthur B; DiCarlo LA; Anand IS
    ESC Heart Fail; 2019 Oct; 6(5):1052-1056. PubMed ID: 31339232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction.
    Suzuki S; Motoki H; Kanzaki Y; Maruyama T; Hashizume N; Kozuka A; Yahikozawa K; Kuwahara K
    ESC Heart Fail; 2020 Oct; 7(5):2752-2761. PubMed ID: 32592265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients.
    Srivastava PK; DeVore AD; Hellkamp AS; Thomas L; Albert NM; Butler J; Patterson JH; Spertus JA; Williams FB; Duffy CI; Hernandez AF; Fonarow GC
    JACC Heart Fail; 2021 Jan; 9(1):28-38. PubMed ID: 33309579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Incident Cancer.
    Tini G; Tanda S; Toma M; Battistoni A; Musumeci B; Barbato E; Canepa M; Ameri P
    Heart Lung Circ; 2024 May; 33(5):704-709. PubMed ID: 38609799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of guideline-directed medical therapy in patients with heart failure on regular hemodialysis.
    Kishihara M; Takada T; Jujo K; Shirotani S; Abe T; Yoshida A; Watanabe S; Hagiwara N
    Int J Cardiol; 2023 Jan; 370():250-254. PubMed ID: 36270495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality and guideline-directed medical therapy in real-world heart failure patients with reduced ejection fraction.
    McCullough PA; Mehta HS; Barker CM; Van Houten J; Mollenkopf S; Gunnarsson C; Ryan M; Cork DP
    Clin Cardiol; 2021 Sep; 44(9):1192-1198. PubMed ID: 34342033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial Differences in Trends and Prognosis of Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction: the Atherosclerosis Risk in Communities (ARIC) Surveillance Study.
    Mathews L; Ding N; Sang Y; Loehr LR; Shin JI; Punjabi NM; Bertoni AG; Crews DC; Rosamond WD; Coresh J; Ndumele CE; Matsushita K; Chang PP
    J Racial Ethn Health Disparities; 2023 Feb; 10(1):118-129. PubMed ID: 35001343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial.
    Cox ZL; Zalawadiya SK; Simonato M; Redfors B; Zhou Z; Kotinkaduwa L; Zile MR; Udelson JE; Lim DS; Grayburn PA; Mack MJ; Abraham WT; Stone GW; Lindenfeld J
    JACC Heart Fail; 2023 Jul; 11(7):791-805. PubMed ID: 37115135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure.
    Löfman I; Szummer K; Olsson H; Carrero JJ; Lund LH; Jernberg T
    J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 29980521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
    Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.